youtube_live
Q2 2027 earnings • in 2 days
See detailschevron_right
BIOCON:NSE
Biocon Ltd
₹351.80
arrow_downward
-0.03%(-0.10) 1D
Oct 30, 3:30:00 PM GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIOCON...
Open
₹352.70
High
₹355.50
Low
₹348.70
Mkt. cap
421.78B
Avg. vol.
2.90M
Volume
2.06M
Dividend
0.14%
Quarterly dividend
₹0.13
Ex-dividend date
Jul 3, 2026
P/E ratio
104.15
52-wk high
₹447.15
52-wk low
₹318.40
EPS
₹3.38
Shares outstanding
600.00M
No. of employees
16K
Open
₹352.70
High
₹355.50
Low
₹348.70
Mkt. cap
421.78B
Avg. vol.
2.90M
Volume
2.06M
Dividend
0.14%
Quarterly dividend
₹0.13
Ex-dividend date
Jul 3, 2026
P/E ratio
104.15
52-wk high
₹447.15
52-wk low
₹318.40
EPS
₹3.38
Shares outstanding
600.00M
No. of employees
16K
News stories
From web sources and news partners
Yahoo Finance
·
24 minutes ago
Wall Street Has Never Faced This Many Market Forces at Once, NYSE Veteran Says
Foreign Policy Journal
·
53 minutes ago
Qualcomm (NASDAQ: QCOM) Faces A Critical Earnings Test As Intel's Memory Warning Casts Doubt On Phone Recovery Thesis
Yahoo Finance
·
1 hour ago
3 Catalysts Cramer Says Could Extend the Nasdaq Sell-Off This Week
CNBC
·
1 day ago
Anthropic's path to the Nasdaq just got a lot bumpier
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16.4K
FoundedNov 29, 1978
HeadquartersBengaluru, Karnataka, India
SectorBiotechnology
Websitebiocon.com